TIME on Wednesday released its first TIME 100 Next list, naming the 100 "rising stars who are shaping the future of business, entertainment, sports, politics, science, health, and more."

Large, brand-name drugmakers could lose $1 trillion in sales and still remain profitable enough to maintain their current investments in research and development—a finding that suggests drug pricing regulations would not substantially harm the drug industry, according to a report released Thursday by West Health and Johns Hopkins Bloomberg School of Public Health.

Harvard Business Review recently released its annual ranking of the 100 "Best-Performing CEOs in the World"—and the list includes nine CEOs in the health care industry.

The number of deaths due to drug-resistant infections in the United States have declined, but the number of these infections are on the rise, indicating that so-called "superbugs" present a greater risk to public health than previously thought, according to a CDC report released Wednesday.

Polling suggests that prescription drug pricing is a big issue for U.S. voters, yet Congress appears no closer to reaching a deal on a comprehensive plan to address rising prescription drug costs.

American Health Line rounds up the latest health care news in the states.

A Gallup poll published Tuesday found that 13% of U.S. adults, or roughly 34 million Americans, know a friend or family member who died in the past five years because he or she could not afford their medical treatment or medication.

University of Maryland now offers a Master's of Science in Medical Cannabis Science and Therapeutics, the first graduate program of its kind in the nation.

CMS on Friday announced that premiums, deductibles, and coinsurance amounts will increase for Medicare Parts A and B for the 2020 coverage year.

An old pricing model called quality-adjusted life years, or QALYs, puts a dollar value on the benefits a drug can have for a patient—and it is increasingly being used by Harvard Medical School's Institute for Clinical and Economic Review to nudge drugmakers into lowering prices.